Rani Therapeutics Financials
| RANI Stock | USD 2.02 0.03 1.51% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.05 | 6.3646 |
|
|
The essential information of the day-to-day investment outlook for Rani Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Rani Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Rani Therapeutics.
Net Income |
|
Rani | Select Account or Indicator |
Understanding current and past Rani Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Rani Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Rani Therapeutics' assets may result in an increase in income on the income statement.
Rani Therapeutics Stock Summary
Rani Therapeutics competes with Vincerx Pharma, Tenaya Therapeutics, Corvus Pharmaceuticals, Alx Oncology, and Lyra Therapeutics. Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company was incorporated in 2012 and is headquartered in San Jose, California. Rani Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 114 people.| Foreign Associate | Israel |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US7530181004 |
| CUSIP | 753018100 |
| Location | California; U.S.A |
| Business Address | 2051 Ringwood Avenue, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.ranitherapeutics.com |
| Phone | 408 457 3700 |
| Currency | USD - US Dollar |
Rani Therapeutics Key Financial Ratios
| Return On Equity | -2.25 | ||||
| Price To Sales | 313.17 X | ||||
| Gross Profit | 2.72 M | ||||
| EBITDA | (65.28 M) | ||||
| Net Income | (33.97 M) |
Rani Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Rani Therapeutics's current stock value. Our valuation model uses many indicators to compare Rani Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Rani Therapeutics competition to find correlations between indicators driving Rani Therapeutics's intrinsic value. More Info.Rani Therapeutics Holdings is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Rani Therapeutics' Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Rani Therapeutics' earnings, one of the primary drivers of an investment's value.Rani Therapeutics Systematic Risk
Rani Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Rani Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Rani Therapeutics correlated with the market. If Beta is less than 0 Rani Therapeutics generally moves in the opposite direction as compared to the market. If Rani Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Rani Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Rani Therapeutics is generally in the same direction as the market. If Beta > 1 Rani Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Rani Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Rani Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Rani Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Rani Therapeutics November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Rani Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Rani Therapeutics Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of Rani Therapeutics Holdings based on widely used predictive technical indicators. In general, we focus on analyzing Rani Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Rani Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 90.76 | |||
| Value At Risk | (7.50) | |||
| Potential Upside | 8.71 |
Complementary Tools for Rani Stock analysis
When running Rani Therapeutics' price analysis, check to measure Rani Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rani Therapeutics is operating at the current time. Most of Rani Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rani Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rani Therapeutics' price. Additionally, you may evaluate how the addition of Rani Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |